[NH:1]1[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.C(N(CC)CC)C.[I-].[K+].[Cl:16][C:17]1[N:22]=[C:21]([S:23][CH3:24])[N:20]2[CH:25]=[C:26]([CH2:28]Cl)[N:27]=[C:19]2[CH:18]=1>CN(C=O)C>[Cl:16][C:17]1[N:22]=[C:21]([S:23][CH3:24])[N:20]2[CH:25]=[C:26]([CH2:28][N:1]3[CH2:6][CH2:5][O:4][CH2:3][CH2:2]3)[N:27]=[C:19]2[CH:18]=1158 mg (1.81 mmol) of morpholine are introduced into 10 ml of DMF at 0° C., and 367 mg (3.63 mmol) of triethylamine and a catalytic amount of potassium iodide are added. A solution of 300 mg of 7-chloro-2-(chloromethyl)-5-(methylthio)imidazo[1,2-c]pyrimidine (Example 26A) in DMF is then slowly added dropwise. The mixture is allowed to reach RT and is stirred at this temperature for a further 16 h. Purification of the crude product by preparative HPLC and drying under high vacuum result in 221.8 mg (41% of theory) of product.